Bifogade filer
SenzaGen obtains expanded OECD approval for GARD®skin – further strengthens position in non-animal regulatory testing
Prenumeration
Beskrivning
| Land | Sverige |
|---|---|
| Lista | First North Stockholm |
| Sektor | Hälsovård |
| Industri | Bioteknik |
SenzaGen’s non-animal test method GARD®skin, which has been approved since 2022 under OECD Test Guideline TG 442E, has now also been included in the newly introduced OECD TG 497. This international guideline describes how different non-animal methods can be combined in regulatory testing to assess whether chemicals may cause skin allergies and how potent they are. The inclusion is expected to increase demand from companies in the chemical and cosmetics industries.
GARD®skin is based on genomics and machine learning and delivers highly reliable and accurate decision-making data. With this inclusion in TG 497, the industry gains improved regulatory access to a high-performing and versatile method that works for both pure chemicals and more complex substances and mixtures that have traditionally been difficult to assess. Since 2022, GARD®skin has also been approved under OECD Test Guideline TG 442E.
“This expanded approval of GARD®skin is an important step in our commercial development. It opens the door to broader use of our method and is expected to drive increased interest from several key customer segments. We bring important new value to regulatory testing, especially when it comes to complex mixtures and difficult-to-test substances, a need we can meet but which previously has lacked effective solutions,” says Peter Nählstedt, CEO and Group President of SenzaGen.